941.0000 36.30 (4.01%)
NSE Nov 17, 2025 13:56 PM
Volume: 116.1K
 

941.00
4.01%
BOB Capital Markets Ltd.
Q2 revenue in line at Rs 6bn but EBITDA/PAT 3%/6% below our estimates due to higher opex and a product mix change
Number of FII/FPI investors decreased from 101 to 92 in Sep 2025 qtr
More from Alivus Life Sciences Ltd.
Recommended